Healthscore 601·6 metrosupdated 2h ago

FDA Delays Postmarket Studies on Drugs Raise Safety Concerns

The FDA's approval of the drug Tavneos, intended for rare autoimmune diseases, has been marred by significant delays in mandated safety studies. With only 21 of 300 patients enrolled, concerns grow over potential risks, including liver damage, as patients remain uninformed about the drug's safety.

Where it's breaking

Los Angeles Boston Hampton Roads Baltimore Philadelphia Miami–Ft. Lauderdale

Local coverage

#1Los Angelesscore 612h ago

FDA Delays Postmarket Studies on Drugs Raise Safety Concerns

#2Bostonscore 542h ago

FDA-Ordered Safety Studies for Drugs Like Tavneos Face Significant Delays

#3Hampton Roadsscore 543h ago

FDA Postmarket Studies Delayed, Leaving Patients in the Dark

#4Baltimorescore 542h ago

FDA Studies on Long-Market Drugs and Devices Still Pending Completion

#5Philadelphiascore 502h ago

The drugs and devices have been on the market for years. But FDA-ordered studies still aren’t done

#6Miami–Ft. Lauderdalescore 362h ago

FDA Delays Postmarket Studies Raise Concerns Over Drug Safety

Sources cited

Original outlets that filed on this story across the contributing metros. Click through for the underlying coverage.

What this is

A national rollup is a story Executive Producer detected breaking in multiple US metros at once. Each contributing market has its own deduplicated cluster from local broadcast, print, government, and community sources — this page links them together so a journalist can see the full national footprint. We are a pointer, not a publisher.Every linked headline goes back to the local cluster and from there to the original outlet — that's the URL to cite. A lead, not the law.